VAR - Varian Medical Systems, Inc.
| Previous Close | 131.77 |
| Open | 132.65 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 132.10 - 133.13 |
| 52 Week Range | 101.42 - 133.41 |
| Volume | 619,306 |
| Avg. Volume | 737,218 |
| Market Cap | 12.05B |
| Beta (3Y Monthly) | 0.89 |
| PE Ratio (TTM) | 33.66 |
| EPS (TTM) | 3.94 |
| Earnings Date | Apr 23, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1998-12-02 |
| 1y Target Est | 136.69 |
- Zacks•4 days ago
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
- Zacks•5 days ago
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
- Zacks•6 days ago
Top Ranked Momentum Stocks to Buy for February 13th
Top Ranked Momentum Stocks to Buy for February 13th
- Zacks•6 days ago
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
Medidata (MDSO) gains from solid segmental performance in Q4.
- Markit•11 days ago
See what the IHS Markit Score report has to say about Varian Medical Systems Inc.
Varian Medical Systems Inc NYSE:VARView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for VAR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VAR. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding VAR totaled $13.33 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•11 days ago
Bright Near-Term Outlook for Medical Instruments Industry
Bright Near-Term Outlook for Medical Instruments Industry
- Zacks•12 days ago
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
- Zacks•12 days ago
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
- Zacks•12 days ago
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
- Zacks•12 days ago
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
- Zacks•13 days ago
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
- Zacks•13 days ago
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
- PR Newswire•13 days ago
Varian Eclipse and TrueBeam Named Category Leaders in the 2019 Best in KLAS: Software and Services Report
PALO ALTO, Calif. , Feb. 6, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its Eclipse ™ treatment planning system and TrueBeam® treatment system have been named Category Leaders in the 2019 Best ...
- Zacks•13 days ago
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
- Zacks•14 days ago
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
- Zacks•14 days ago
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
- Zacks•14 days ago
3 Medical Instruments Stocks Likely to Beat Estimates in Q4
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
- PR Newswire•14 days ago
Varian Demonstrating Smarter Cancer Care Solutions at HIMSS19
PALO ALTO, Calif. , Feb. 5, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be demonstrating a portfolio of smarter cancer care software solutions, February 12-14 in Orlando, FL at HIMSS19, ...
- Simply Wall St.•14 days ago
Should You Be Worried About Insider Transactions At Varian Medical Systems, Inc. (NYSE:VAR)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares Read More...
- Zacks•15 days ago
Omnicell Solid on Geographic Expansion Amid Stiff Competition
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
- Zacks•17 days ago
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
- Zacks•18 days ago
PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y
PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.
- Zacks•18 days ago
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
- Zacks•18 days ago
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
- Zacks•18 days ago
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
